Cognitive Systems Continues to Expand Global Reach with Airties WiFi 6 Portfolio
10.3.2021 13:00:00 EET | Business Wire | Press release
Cognitive Systems Corp. announced today an integration with Airties to offer its patented WiFi Motion technology across Airties’ portfolio of WiFi 6 solutions. Cognitive’s WiFi Motion will make it easier than ever for service providers to access this revolutionary sensing technology.
Over the past six years, Cognitive Systems has designed, developed, and implemented the first and most sophisticated WiFi-enabled motion sensing software on the market. WiFi Motion leverages connected IoT devices to turn the entire home into a motion-sensing network, introducing an innovative way to use WiFi. With 37 ISPs currently offering WiFi Motion around the globe, millions of homes already have access to this new service and its growing number of applications.
“Service providers are looking for new ways to differentiate from competitors and retain customers. Our priority is providing smart WiFi solutions that offer value beyond connectivity,” said Taj Manku, Co-Founder and CEO of Cognitive Systems. “Like us, Airties aims to shape the next generation of wireless solutions and see the possibilities for motion sensing, from smarter home monitoring to a higher standard of eldercare. We’re doing the legwork with their Wi-Fi 6 portfolio to get WiFi Motion ready for some forward-thinking Airties service providers who want to offer these benefits to their customers as soon as possible.”
Cognitive Systems and Airties share a commitment to staying ahead of the market, both by being active members of the Wireless Broadband Alliance (WBA) and closely following emerging trends. In addition to the current home monitoring capabilities, WiFi Motion’s highly anticipated eldercare solution will bring peace of mind to caregivers by providing discreet wellness monitoring without the need for cameras or wearable devices. The market for remote wellness monitoring products is growing rapidly. Soon customers will be able to receive notifications and gain valuable insights into not only their homes but also the homes of loved ones.
“As a pioneer and leader in Wi-Fi sensing, we are pleased to be working with Cognitive Systems on new Wi-Fi 6 solutions,” said Metin Taskin, Co-Founder and CTO of Airties. “Cognitive’s product roadmap has a realistic game plan for both implementation and longevity. The integration of WiFi Motion and Airties can enable service providers to offer innovative value-add Wi-Fi services to their customers.”
About Cognitive Systems
Cognitive Systems Corp. is on a mission to transform the way WiFi networks are used. Its flagship technology, WiFi Motion™, uses wireless signals to sense motion in the home. WiFi Motion harnesses artificial intelligence and predictive analytics to reliably identify and localize motion for the smart home, home monitoring, and wellness monitoring markets. This patented technology is layered onto existing WiFi networks without additional hardware to enhance service provider and router manufacturer offerings.
www.cognitivesystems.com
https://www.linkedin.com/company/cognitive-systems-corp-/
About Airties
Founded in 2004, Airties is the most widely deployed provider of managed in-home Wi-Fi solutions to operators around the globe. The company offers Smart Wi-Fi software, a cloud-based management platform, and Mesh extenders. Service providers turn to Airties for the design, implementation, and ongoing optimization of their customers’ broadband experience. With an installed base of over 30 million homes, Airties’ customers include: Altice USA, AT&T, Singtel, Sky, Telia, Telstra, and many others. More information is available at www.Airties.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005132/en/
Contact information
Cognitive Systems Corp.
Jillian Colucci
jcolucci@getproof.com
416-801-9851
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom